Long-term relationship of ovulation-stimulating drugs to breast cancer risk
- PMID: 24700523
- PMCID: PMC3979528
- DOI: 10.1158/1055-9965.EPI-13-0996
Long-term relationship of ovulation-stimulating drugs to breast cancer risk
Abstract
Background: Although fertility drugs stimulate ovulation and raise estradiol levels, their effect on breast cancer risk remains unresolved.
Methods: An extended follow-up was conducted among a cohort of 12,193 women evaluated for infertility between 1965 and 1988 at five U.S. sites. Follow-up through 2010 was achieved for 9,892 women (81.1% of the eligible population) via passive as well as active (questionnaires) means. Cox regression determined HRs and 95% confidence intervals (CI) for fertility treatments adjusted for breast cancer risk factors and causes of infertility.
Results: During 30.0 median years of follow-up (285,332 person-years), 749 breast cancers were observed. Ever use of clomiphene citrate among 38.1% of patients was not associated with risk (HR = 1.05; 95% CI, 0.90-1.22 vs. never use). However, somewhat higher risks were seen for patients who received multiple cycles, with the risk for invasive cancers confirmed by medical records being significantly elevated (HR = 1.69; 95% CI, 1.17-2.46). This risk remained relatively unchanged after adjustment for causes of infertility and multiple breast cancer predictors. Gonadotropins, used by 9.6% of patients, mainly in conjunction with clomiphene, showed inconsistent associations with risk, although a significant relationship of use with invasive cancers was seen among women who remained nulligravid (HR = 1.98; 95% CI, 1.04-3.60).
Conclusions: Although the increased breast cancer risk among nulligravid women associated with gonadotropins most likely reflects an effect of underlying causes of infertility, reasons for the elevated risk associated with multiple clomiphene cycles are less clear.
Impact: Given our focus on a relatively young population, additional evaluation of long-term fertility drug effects on breast cancer is warranted.
Conflict of interest statement
Figures
Similar articles
-
Risk of cancer after assisted reproduction: a review of the available evidences and guidance to fertility counselors.Eur Rev Med Pharmacol Sci. 2018 Nov;22(22):8042-8059. doi: 10.26355/eurrev_201811_16434. Eur Rev Med Pharmacol Sci. 2018. PMID: 30536354 Review.
-
Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort.Fertil Steril. 2013 Dec;100(6):1660-6. doi: 10.1016/j.fertnstert.2013.08.008. Epub 2013 Sep 5. Fertil Steril. 2013. PMID: 24011610 Free PMC article.
-
Fertility drugs and endometrial cancer risk: results from an extended follow-up of a large infertility cohort.Hum Reprod. 2013 Oct;28(10):2813-21. doi: 10.1093/humrep/det323. Epub 2013 Aug 13. Hum Reprod. 2013. PMID: 23943795 Free PMC article.
-
Long-term effects of ovulation-stimulating drugs on cancer risk.Reprod Biomed Online. 2007 Jul;15(1):38-44. doi: 10.1016/s1472-6483(10)60689-x. Reprod Biomed Online. 2007. PMID: 17623533 Review.
-
Ovarian cancer risk after the use of ovulation-stimulating drugs.Obstet Gynecol. 2004 Jun;103(6):1194-203. doi: 10.1097/01.AOG.0000128139.92313.74. Obstet Gynecol. 2004. PMID: 15172852
Cited by
-
The association between endometriosis and risk of endometrial cancer and breast cancer: a meta-analysis.BMC Womens Health. 2022 Nov 18;22(1):455. doi: 10.1186/s12905-022-02028-x. BMC Womens Health. 2022. PMID: 36401252 Free PMC article.
-
Association between fertility treatments and breast cancer risk in women with a family history or BRCA mutations: a systematic review and meta-analysis.Front Endocrinol (Lausanne). 2022 Sep 13;13:986477. doi: 10.3389/fendo.2022.986477. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36176466 Free PMC article.
-
Fertility treatment and breast-cancer incidence: meta-analysis.BJS Open. 2022 Jan 6;6(1):zrab149. doi: 10.1093/bjsopen/zrab149. BJS Open. 2022. PMID: 35143625 Free PMC article.
-
Executive Summary of the Early-Onset Breast Cancer Evidence Review Conference.Obstet Gynecol. 2020 Jun;135(6):1457-1478. doi: 10.1097/AOG.0000000000003889. Obstet Gynecol. 2020. PMID: 32459439 Free PMC article. Review.
-
Do the Fertility Drugs Increase the Risk of Cancer? A Review Study.Front Endocrinol (Lausanne). 2019 May 24;10:313. doi: 10.3389/fendo.2019.00313. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31191449 Free PMC article. Review.
References
-
- Fathalla MF. Incessant ovulation--a factor in ovarian neoplasia? Lancet. 1971;2(7716):163. - PubMed
-
- Parazzini F, La Vecchia C, Negri E, Franceschi S, Tozzi L. Lifelong menstrual pattern and risk of breast cancer. Oncology. 1993;50(4):222–5. - PubMed
-
- Sovino H, Sir-Petermann T, Devoto L. Clomiphene citrate and ovulation induction. Reprod Biomed Online. 2002;4(3):303–10. - PubMed
-
- Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia. 2002;7(1):3–15. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical